scholarly journals Retracted: Experience of cooperation in the creation of hematopoietic stem cells donors registry

2016 ◽  
Vol 97 (5) ◽  
pp. 777-780
Author(s):  
M A Murzabekova ◽  
J S Neredko ◽  
Ya M Marchenko

This article has been retracted. Aim. To evaluate the experience of participating in the creation of a national registry of hematopoietic stem cells donors.Methods. Potential hematopoietic stem cells donor filled out a questionnaire, after the examination, he was assigned an individual donor code (bar code). The results of typing and questionnaires are placed on the registry of potential hematopoietic stem cells donors. Maintenance of HLA-typed potential hematopoietic stem cells donors registry and the selection of compatible «donor-recipient» pairs in RMSPC «Rosplazma» were performed using a specialized program «Prometheus» (Steiner Ltd., Czech Republic).Results. 484 donors, who were indigenous peoples of Stavropol and Stavropol Krai, as well as representatives of the North Caucasus small nations of different nationalities, were included into the registry for the period from 08.20.2013 to 20.06.2014. Age ranged from 19 to 42 years. As of 31.10.2015, 31 491 potential hematopoietic stem cells donors (54% - female, 46% - male) were included into the registry, 28 509 donors were typed: 24 310 for HLA - A, B, C, and DRB1 loci; 2305 for HLA - A, B, C, DRB1, and DQB1 loci; 1894 for HLA - A, B, and DRB1 loci. The registry has the highest number of A-B-DRB1 typed donors among Russian registries. New HLA-alleles in the Russian populations were revealed in 57 cases for 28 509 typing (1:500).Conclusion. There is a clear need to enhance cooperation of RMSPC «Rosplazma» with all regions of Russia and create unified national registry of hematopoietic stem cells donors with its inclusion in international databases.

Transfusion ◽  
2008 ◽  
Vol 48 (3) ◽  
pp. 561-566 ◽  
Author(s):  
Hirofumi Yura ◽  
Yasuhiro Kanatani ◽  
Masayuki Ishihara ◽  
Bonpei Takase ◽  
Masaki Nambu ◽  
...  

Science ◽  
1986 ◽  
Vol 233 (4765) ◽  
pp. 776-778 ◽  
Author(s):  
A. Flake ◽  
M. Harrison ◽  
N. Adzick ◽  
E. Zanjani

Blood ◽  
2003 ◽  
Vol 102 (2) ◽  
pp. 506-513 ◽  
Author(s):  
Derek A. Persons ◽  
Esther R. Allay ◽  
Nobukuni Sawai ◽  
Phillip W. Hargrove ◽  
Thomas P. Brent ◽  
...  

AbstractSuccessful gene therapy of β-thalassemia will require replacement of the abnormal erythroid compartment with erythropoiesis derived from genetically corrected, autologous hematopoietic stem cells (HSCs). However, currently attainable gene transfer efficiencies into human HSCs are unlikely to yield sufficient numbers of corrected cells for a clinical benefit. Here, using a murine model of β-thalassemia, we demonstrate for the first time that selective enrichment in vivo of transplanted, drug-resistant HSCs can be used therapeutically and may therefore be a useful approach to overcome limiting gene transfer. We used an oncoretroviral vector to transfer a methylguanine methyltransferase (MGMT) drug-resistance gene into normal bone marrow cells. These cells were transplanted into β-thalassemic mice given nonmyeloablative pretransplantation conditioning with temozolomide (TMZ) and O6-benzylguanine (BG). A majority of mice receiving 2 additional courses of TMZ/BG demonstrated in vivo selection of the drug-resistant cells and amelioration of anemia, compared with untreated control animals. These results were extended using a novel γ-globin/MGMT dual gene lentiviral vector. Following drug treatment, normal mice that received transduced cells had an average 67-fold increase in γ-globin expressing red cells. These studies demonstrate that MGMT-based in vivo selection may be useful to increase genetically corrected cells to therapeutic levels in patients with β-thalassemia.


Sign in / Sign up

Export Citation Format

Share Document